NUTX
Nutex Health Inc.
Next earnings Aug 12, 2026 · consensus $4.60 EPS, $219M rev
Last earnings +6.4% on 2026-04-30
$166.40
▲ +11.60%$166.40▲ +42.40%
over 1Y
L $80.92EODHDH $190.49
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+11.6%
1W+10.8%
1M+39.3%
3M+77.4%
YTD+12.3%
1Y+42.4%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 9 analysts
Buy
Explosive numbers shadowed by a securities class action alleging the very accounting/IDR revenue driving the boom is misstated.
Revenue $875M · FY2025
The read
It screens cheap (~139% below fair value), but the weak fundamentals are why — more potential value trap than bargain.
On the surface NUTX looks like a fundamental dream: FY2025 revenue of $875M (+82.4% YoY), operating income of $276M (31.5% margin), operating cash flow of $248M (+971.7%), cash of $186M, and stockholders' equity nearly 2.5x'd to $329M. At $146.95 the stock trades at just 14x diluted EPS of $10.48 and 1.2x sales — optically cheap for a business throwing off these margins. ROE of 21.5% and a current ratio of ~3.4x (current assets $539M vs current liabilities $158M) round out a balance sheet that, in isolation, screams quality at a discount.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $332M | $219M | $248M | $480M | $875M |
| Gross profit | $179M | $15.4M | $34.8M | $196M | $444M |
| Operating income | $170M | -$407M | -$31.8M | $131M | $276M |
| Net income | $133M | -$425M | -$45.8M | $52.1M | $70.8M |
| Diluted EPS | $0.22 | -$100.36 | -$10.39 | $9.69 | $10.48 |
| Net margin | 40.0% | -193.7% | -18.5% | 10.9% | 8.1% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$1.02B
EV / EBITDA3.4
EV / Sales1.2
EV / FCF4.1
P / FCF4.7
PEG (trailing)0.44
Earnings yield6.1%
FCF yield21.2%
Quality & risk
ROIC (est.)58.5%
Free cash flow$246M
Total debt$42.5M
Net cash$143M
Altman Z-Score3.41 safe
Piotroski F-Score7/9
Capital returns
Buyback yield0.4%
Dividend yield (est.)—
Shareholder yield0.4%
Shares Δ YoY+26.0%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRecent disclosure tone has been improving.
- 8-K Earnings results2026-04-30
Q1'26 10-Q filed on time, signals return to normal SEC reporting cadence
- 10-Q Quarterly report2026-04-30
Q1'26 10-Q filed on time, signals return to normal SEC reporting cadence
- 8-K Shareholder vote2026-04-23
Annual meeting voting results disclosed; routine governance, no operational impact
- DEF 14A Proxy statement2026-03-13
2026 proxy: director slate, say-on-pay, auditor ratification; routine governance
- 8-K Earnings results2026-03-05
FY25 10-K: strong growth but securities class action + derivative suits overhang
- 10-K Annual report2026-03-05
FY25 10-K: strong growth but securities class action + derivative suits overhang
- 8-K Other event2025-11-24
Other event/exhibit filing, likely tied to restatement cleanup and litigation overhang
- 8-K Earnings results2025-11-19
Q3 2025 10-Q filed after NT 10-Q delay; reporting brought current
- 10-Q Quarterly report2025-11-19
Q3 2025 10-Q filed after NT 10-Q delay; reporting brought current
Recent filings
all on EDGAR ↗4Period ending 2026-06-042026-06-04open ↗4Period ending 2026-05-282026-05-29open ↗SCHEDULE 13G/AFiling2026-05-07open ↗8-KPeriod ending 2026-04-302026-04-30open ↗10-QPeriod ending 2026-03-312026-04-30open ↗SCHEDULE 13GFiling2026-04-27open ↗4Period ending 2026-04-232026-04-24open ↗4Period ending 2026-04-232026-04-24open ↗4Period ending 2026-04-232026-04-24open ↗4Period ending 2026-04-232026-04-24open ↗8-KPeriod ending 2026-04-232026-04-23open ↗4Period ending 2026-04-092026-04-10open ↗
Frequently asked
- Is Nutex Health Inc. (NUTX) a buy?
- NUTX currently carries a Avoid rating with 4/5 conviction, derived from its latest SEC filings. Explosive numbers shadowed by a securities class action alleging the very accounting/IDR revenue driving the boom is misstated.
- What is NUTX's fair value?
- A Modified-Graham model based on NUTX's SEC fundamentals estimates a fair value of about $398.24. It is an estimate from reported earnings, not a price target.
- Is NUTX overvalued or undervalued?
- Against a Modified-Graham fair-value estimate, NUTX currently appears undervalued relative to its SEC-grounded earnings power.
- What is Nutex Health Inc.'s quality score?
- NUTX scores 82.78431372549018/100 (grade A-) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001479681, latest 10-Q filed 2026-04-30) · EODHD · analysis by claude-code · as of 6/25/2026, 2:20:19 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.